Molecular Cancer Therapeutics Journal

Overview

publication venue for

• Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation 2024
• Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation. 2024
• Preclinical Development of the Class-I-Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors 2022
• p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer 2015
• Microtubule targeting antimitotic drugs induce a lower mitotic arrest than clinically less effective antimitotic Eg5 inhibitors in mouse xenografts. 2013
Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate 2008
Doxorubicin-formaldehyde conjugates targeting α_vβ₃ integrin 2004
Rational combination of mTOR and Aurora kinase A inhibition in preclinical models of triple-negative breast cancer 2018
... more

Research

keywords

• 1112 Oncology and Carcinogenesis, 1115 Pharmacology and Pharmaceutical Sciences